Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Senseonics Holdings, Inc. (SENS) provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Senseonics is a medical technology company focused on the development and manufacturing of long-term implantable continuous glucose monitoring (CGM) systems, and its filings offer detailed insight into its financial condition, capital structure, and corporate actions.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, and financial statements related to its Eversense 365 and Eversense E3 glucose monitoring products. Form 8-K current reports disclose material events, such as preliminary financial results, the implementation of a 1-for-20 reverse stock split, special stockholder meetings, and updates on commercialization plans and collaborations.
Investors can also review proxy materials, such as the DEF 14A definitive proxy statement for the special meeting of stockholders that authorized the reverse stock split and proportional reduction in authorized shares. In addition, a Form 25 filing documents the voluntary removal of Senseonics’ common stock from listing and registration on the NYSE American in connection with the transfer of its listing to the Nasdaq Global Select Market.
Through this page, users can follow how Senseonics reports on topics such as revenue updates, capital structure changes, and governance matters. Real-time updates from EDGAR ensure that new filings, including Forms 8-K, 10-Q, and 10-K, appear as they are submitted. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections, and clarify technical language, making it easier to understand how Senseonics’ regulatory disclosures relate to its long-term implantable CGM business.
For those researching SENS, this filings page serves as a central location to review the company’s official SEC documents, track its corporate history, and analyze how its medical technology operations and public company obligations intersect.
ROEDER DOUGLAS A reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Douglas A. Roeder received 2,218 shares of common stock as a grant in lieu of cash board fees. The shares were valued at $6.65 each, matching the Nasdaq closing price on April 1, 2026, for a total of $14,749.70 in compensation value.
This was a compensation-related award under the company’s non-employee director compensation policy, not an open-market purchase. After this grant, Roeder directly holds 121,949 shares of Senseonics common stock.
Prince Douglas S reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. director Douglas S. Prince received 1,221 shares of common stock on April 1, 2026 as a grant. The shares were issued under the non-employee director compensation policy in lieu of quarterly retainer fees, based on $8,119.65 divided by the $6.65 closing price. Following this award, he directly holds 57,964 common shares.
Fiorentino Edward reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. reported that director Edward Fiorentino received a grant of common stock as board compensation. On April 1, 2026, he was issued 2,124 shares under the non-employee director compensation policy in lieu of a $14,124.60 quarterly cash retainer at $6.65 per share. Following this award, he directly holds 73,487 shares of Senseonics common stock.
Steven Edelman reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Steven Edelman received a stock grant as part of his board compensation. He was awarded 1,936 shares of common stock, valued at $12,874.40 based on a $6.65 closing price on April 1, 2026, in lieu of quarterly cash retainer fees.
Following this grant, Edelman directly holds 78,829 shares of Senseonics common stock. This was a compensation-related award rather than an open-market purchase or sale, and no derivative securities are reported in this filing.
Senseonics Holdings, Inc. is soliciting proxies for its virtual 2026 Annual Meeting to be held on May 20, 2026. The record date is March 26, 2026, when 41,795,466 shares were outstanding. Key proposals include the election of three Class I directors (Timothy T. Goodnow, Francine R. Kaufman and Sharon Larkin), an advisory say-on-pay vote and a say-on-frequency vote, ratification of KPMG LLP as independent auditors, approval to increase authorized common shares from 70,000,000 to 140,000,000, and approval of the Senseonics Holdings, Inc. 2026 Equity Incentive Plan.
The proxy discloses reserve and capitalization context as of the record date: 41,795,466 shares outstanding, aggregate reserved shares of 14,233,357 across plans and warrants, and 13,971,177 unissued, unreserved shares. The company reported $15.8 million gross profit for the twelve months ended December 31, 2025 and an accumulated deficit of $1 billion. The Board recommends a vote FOR all proposals.
Senseonics Holdings, Inc. director Douglas A. Roeder purchased additional company stock in the open market. On March 13, 2026, he bought 17,500 shares of common stock at $5.73 per share. Following this transaction, his direct ownership increased to 119,731 shares, reflecting a meaningful personal investment in the company.
Senseonics Holdings, Inc. President and CEO Timothy T. Goodnow made an open-market purchase of common stock. On March 13, 2026, he bought 17,225 shares at a weighted average price of $5.79 per share, bringing his direct ownership to 651,243 shares after the transaction.
Senseonics Holdings, Inc. has entered into a series of Local Asset Purchase Agreements with Ascensia Diabetes Care to acquire additional assets tied to commercial Eversense CGM activities in Italy, Germany, Spain and Sweden. These European Asset Purchases build on a prior master asset purchase agreement covering U.S. rights.
At each European closing, expected on or before June 30, 2026 subject to customary conditions and required consents, Senseonics will pay cash based on the net book value of the related assets and assumed liabilities. A separate Transition Services Agreement will have Ascensia provide logistics, IT, finance, regulatory and other support in the European territories, generally through dates up to June 30, 2026, to help ensure an orderly handover and continuity of Eversense operations.
Senseonics Holdings, Inc. files its Annual Report describing a diabetes-focused medical technology business built around Eversense, a long-term implantable continuous glucose monitoring system. The company highlights FDA approval and U.S. launch of its 365-day Eversense 365 system in 2024.
The report details a major shift in commercial strategy as Senseonics acquires Eversense commercial assets from Ascensia, regains U.S. marketing rights, and from January 1, 2026 is entitled to 100% of Eversense revenues in key European territories. The company outlines pivotal trials, upcoming Gemini and Freedom sensor platforms, extensive patent protection through 2049, and notes that 41,770,466 shares of common stock were outstanding as of February 20, 2026.
Senseonics Holdings, Inc. reported strong growth for the fourth quarter and full year 2025 while continuing to invest heavily in commercialization of its Eversense 365 long-term CGM system. Q4 revenue rose to $14.3 million, up from $8.3 million, driven mainly by U.S. sales.
For 2025, total revenue increased to $35.3 million from $22.5 million, and gross profit improved sharply to $15.8 million from $0.5 million as one-time transition charges rolled off and margins on the 365-day product improved. The annual net loss narrowed to $69.1 million, or $1.66 per share, from $78.6 million, reflecting better gross profit offset by higher selling, general and administrative expenses as the company took Eversense commercialization and distribution back in-house and ramped direct-to-consumer marketing.
Cash, cash equivalents and investments totaled $94.3 million with indebtedness of $35.3 million at December 31, 2025. For 2026, Senseonics expects global net revenue of $58–$62 million, implying 65–76% growth, and targets gross margins of about 50% as it completes the transition from Ascensia and expands Eversense 365 globally and into automated insulin delivery integrations.